Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery
Primary Purpose
Cesarean Section, Infection
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Cefazolin (Timing of Antibiotic Prophylaxis)
Sponsored by

About this trial
This is an interventional prevention trial for Cesarean Section focused on measuring Antibiotic, Prophylaxis, Cesarean, Infection, Antibiotic prophylaxis
Eligibility Criteria
Inclusion Criteria:
- Patients 18 years of age or older
- Any patient at term (>37 weeks gestation) undergoing a scheduled cesarean delivery
Exclusion Criteria:
- Women younger than 18 years
- Patients who are febrile during or prior to screening or with a diagnosis of clinical suspicion of endometritis (with or without maternal fever)
- Patients who present with ruptured membranes
- Known fetal malformations
- Contraindications to cefazolin administration (known anaphylactic reaction to penicillins or known cephalosporin allergy)
- Any exposure to antibiotics in one week prior to cesarean delivery
- Obstetrical indication for an emergent cesarean delivery
- Patients taking glucocorticoids or other immunosuppressant therapy
Sites / Locations
- Long Beach Memorial Medical Center
- University of California, Irvine Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
1
2
Arm Description
Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
Patients who receive antibiotic prophylaxis prior to skin incision
Outcomes
Primary Outcome Measures
To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping
Secondary Outcome Measures
To assess incidence of neonatal infectious morbidity (i.e. rates of sepsis work-up, confirmed sepsis, and length of hospital stay) between two study arms
Full Information
NCT ID
NCT00811603
First Posted
December 17, 2008
Last Updated
September 17, 2009
Sponsor
MemorialCare
Collaborators
University of California, Irvine
1. Study Identification
Unique Protocol Identification Number
NCT00811603
Brief Title
Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery
Official Title
Optimal Timing for Antibiotic Prophylaxis for Elective Cesarean Delivery in Term Gestations: A Randomized, Controlled Trial Comparing Cefazolin Administration Prior to Skin Incision Versus Following Cord Clamping
Study Type
Interventional
2. Study Status
Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
MemorialCare
Collaborators
University of California, Irvine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the rates of maternal and neonatal infectious morbidity in gravid patients undergoing cesarean delivery. Specifically, the investigators are examining whether the timing of antibiotic administration has any effect on rates of maternal and neonatal infections, neonatal sepsis work-up and length of hospital stay.
Detailed Description
Nearly fifty years have passed since Burke et al first demonstrated in animal model the reduction of infection rates in contaminated skin incisions with administration of antibiotic prophylaxis. Further research in the area confirmed the benefit of prophylactic antibiotics in human subjects. Patients who develop surgical infections are 60% more likely to spend time in intensive care unit, five times more likely to be readmitted to the hospital, and have twice the mortality rate compared to patients without infections. As a result the potential health care costs are staggering. Recently, the National Surgical Infection Prevention Project endorsed the recommendation that antibiotic prophylaxis should be administered within 60 minutes before skin incision. This model has been universally accepted in all surgical fields with the exception of obstetrics.
Cesarean delivery has been shown to be the most important risk factor for post-partum maternal infection. In fact, women undergoing cesarean delivery have a five to twenty-fold greater risk for developing infection compared to those undergoing vaginal delivery. Recent review by Cochrane Database found that there is an inconsistent and variable application of current recommendations in regard to appropriate timing, administration and choice of drug used for antibiotic prophylaxis at the time of cesarean delivery. Cesarean section holds a unique position amongst all the surgical procedures as being the only one where prophylactic antibiotics are administered after the incision is made. The concern for intrapartum fetal exposure of prophylactic antibiotics suppressing microbial growth and thereby masking neonatal sepsis led to a tradition of delaying antibiotic administration until umbilical cord clamping. While a recent study demonstrated that antibiotic levels do indeed reach therapeutic levels within cord blood very quickly after administration to the mother, no adverse outcomes to the newborns have ever been documented as a result. To date only four studies have looked at the timing of prophylactic administration at the time of cesarean section.
In 1982, Cunningham et al randomized 642 women "at high risk for infection following cesarean delivery" to receiving antibiotics before or after cord clamping. The authors demonstrated that there was no difference between uterine infection rates between the two groups. While significantly more infants exposed to intrapartum maternal antibiotics were evaluated for sepsis, there were no cases of neonatal bacteremia in either group. However, it should be noted that the pediatricians in this study were fully aware of whether antibiotics had been given before or after cord clamping. Wax et al revisited the issue by randomizing 90 consecutive term women in labor to receiving cefazolin preoperatively or after skin incision. While the authors failed to show any statistical significance between two groups, this study was clearly underpowered as only four cases achieved primary outcomes. Furthermore, the authors failed to demonstrate a significant increase is suspected sepsis in newborns whose mothers received cefazolin preoperatively. In 2005, Thigpen et al once again demonstrated that there was no disadvantage to the infant in regard to infectious morbidity. In addition, there was no difference in maternal infectious morbidity regardless of when antibiotics were administered. However, the results are questionable as nearly a quarter of all subjects received penicillin for GBS prophylaxis. Finally, Sullivan included 357 women in a well designed randomized, double-blinded study that demonstrated a statistically significant reduction in maternal infectious morbidity when the antibiotics where administered preoperatively. Not only was there no difference between two groups in regard to neonatal infection, but there was actually significantly fewer NICU admission days in preoperative antibiotic group.
Despite the evidence that preoperative prophylactic antibiotics pose no harm to the fetus, obstetrics has been slow to adopt this practice. It is no wonder that cesarean infection rates have been shown to be considerably higher than comparable surgical procedures. While the evidence clearly demonstrates the absence of negative impact of preoperative antibiotics on neonatal outcomes, a contemporary scientific evaluation of the reduction in maternal infectious morbidity is warranted before adopting this practice on universal basis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cesarean Section, Infection
Keywords
Antibiotic, Prophylaxis, Cesarean, Infection, Antibiotic prophylaxis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
Arm Title
2
Arm Type
Experimental
Arm Description
Patients who receive antibiotic prophylaxis prior to skin incision
Intervention Type
Drug
Intervention Name(s)
Cefazolin (Timing of Antibiotic Prophylaxis)
Intervention Description
Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
Primary Outcome Measure Information:
Title
To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
To assess incidence of neonatal infectious morbidity (i.e. rates of sepsis work-up, confirmed sepsis, and length of hospital stay) between two study arms
Time Frame
6 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients 18 years of age or older
Any patient at term (>37 weeks gestation) undergoing a scheduled cesarean delivery
Exclusion Criteria:
Women younger than 18 years
Patients who are febrile during or prior to screening or with a diagnosis of clinical suspicion of endometritis (with or without maternal fever)
Patients who present with ruptured membranes
Known fetal malformations
Contraindications to cefazolin administration (known anaphylactic reaction to penicillins or known cephalosporin allergy)
Any exposure to antibiotics in one week prior to cesarean delivery
Obstetrical indication for an emergent cesarean delivery
Patients taking glucocorticoids or other immunosuppressant therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth Chan, MD
Organizational Affiliation
Memorial Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Long Beach Memorial Medical Center
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
University of California, Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery
We'll reach out to this number within 24 hrs